314 related articles for article (PubMed ID: 16763827)
1. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Dailly E; Tribut O; Tattevin P; Arvieux C; Perré P; Raffi F; Jolliet P
Eur J Clin Pharmacol; 2006 Jul; 62(7):523-6. PubMed ID: 16763827
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Le Tiec C; Barrail A; Goujard C; Taburet AM
Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
[TBL] [Abstract][Full Text] [Related]
5. Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.
Di Biagio A; Rosso R; Loregian A; Pagni S; Sormani MP; Cenderello G; Palù G; Viscoli C
J Infect Chemother; 2012 Aug; 18(4):587-90. PubMed ID: 22422300
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
Kreitchmann R; Best BM; Wang J; Stek A; Caparelli E; Watts DH; Smith E; Shapiro DE; Rossi S; Burchett SK; Hawkins E; Byroads M; Cressey TR; Mirochnick M
J Acquir Immune Defic Syndr; 2013 May; 63(1):59-66. PubMed ID: 23392467
[TBL] [Abstract][Full Text] [Related]
7. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
Taburet AM; Piketty C; Chazallon C; Vincent I; Gérard L; Calvez V; Clavel F; Aboulker JP; Girard PM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2091-6. PubMed ID: 15155205
[TBL] [Abstract][Full Text] [Related]
8. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
[TBL] [Abstract][Full Text] [Related]
9. Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
Mirochnick M; Best BM; Stek AM; Capparelli EV; Hu C; Burchett SK; Rossi SS; Hawkins E; Basar M; Smith E; Read JS;
J Acquir Immune Defic Syndr; 2011 Apr; 56(5):412-9. PubMed ID: 21283017
[TBL] [Abstract][Full Text] [Related]
10. Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.
Poirier JM; Robidou P; Jaillon P
Ther Drug Monit; 2005 Apr; 27(2):186-92. PubMed ID: 15795650
[TBL] [Abstract][Full Text] [Related]
11. Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
Colbers A; Hawkins D; Hidalgo-Tenorio C; van der Ende M; Gingelmaier A; Weizsäcker K; Kabeya K; Taylor G; Rockstroh J; Lambert J; Moltó J; Wyen C; Sadiq ST; Ivanovic J; Giaquinto C; Burger D;
Antivir Ther; 2015; 20(1):57-64. PubMed ID: 24992294
[TBL] [Abstract][Full Text] [Related]
12. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
Dailly E; Allavena C; Bouquié R; Deslandes G; Raffi F; Jolliet P
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):42-6. PubMed ID: 23148588
[TBL] [Abstract][Full Text] [Related]
13. Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients.
Droste JA; Kearney BP; Hekster YA; Burger DM
J Acquir Immune Defic Syndr; 2006 Jan; 41(1):37-43. PubMed ID: 16340471
[TBL] [Abstract][Full Text] [Related]
14. Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
Moltó J; Deig E; Valle M; Maria Llibre J; Miranda C; Cedeño S; Valero S; Negredo E; Clotet B
Ther Drug Monit; 2010 Feb; 32(1):93-6. PubMed ID: 20040897
[TBL] [Abstract][Full Text] [Related]
15. Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.
Wang X; Boffito M; Zhang J; Chung E; Zhu L; Wu Y; Patterson K; Kashuba A; Tebas P; Child M; Mahnke L; Bertz R
AIDS Patient Care STDS; 2011 Sep; 25(9):509-15. PubMed ID: 21770762
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.
Foissac F; Blanche S; Dollfus C; Hirt D; Firtion G; Laurent C; Treluyer JM; Urien S
Br J Clin Pharmacol; 2011 Dec; 72(6):940-7. PubMed ID: 21649692
[TBL] [Abstract][Full Text] [Related]
17. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Bifano M; Hwang C; Oosterhuis B; Hartstra J; Grasela D; Tiessen R; Velinova-Donga M; Kandoussi H; Sevinsky H; Bertz R
Antivir Ther; 2013; 18(7):931-40. PubMed ID: 23963204
[TBL] [Abstract][Full Text] [Related]
18. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
[TBL] [Abstract][Full Text] [Related]
19. Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
Dailly E; Raffi F; Biron C; Allavena C; Jolliet P
Fundam Clin Pharmacol; 2008 Feb; 22(1):101-4. PubMed ID: 18251726
[TBL] [Abstract][Full Text] [Related]
20. Atazanavir/ritonavir: a review of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
